Rationale: Patients with transient ischemic attack or minor stroke are at high risk of early recurrent cerebrovascular events. Anticoagulation with heparin or warfarin acutely after ischemic stroke is at least as efficacious as aspirin for preventing recurrent events but is associated with an increased risk of clinical worsening due to hemorrhagic transformation.
Introduction and rationale
The risk of recurrent cerebrovascular events following a minor ischemic stroke or transient ischemic attack (TIA) is as high as 17% in the first three months with most events occurring early in this interval. 1 The period shortly following TIA/minor stroke represents an opportunity for high-impact intervention. Antiplatelet agents are recommended immediately after TIA/minor stroke. 2 Although short-term combination antiplatelet therapy has been shown to reduce early recurrent stroke, it has not become standard of care owing to unique features of the population in a single trial and a second large trial is ongoing. 3 Early parenteral anticoagulant use in this population is associated with reduced early recurrent stroke rates, but greater risk of symptomatic hemorrhagic transformation (HT). 4, 5 Current guidelines recommend against routine anticoagulation in acute ischemic stroke. 2 Dabigatran, a direct oral anticoagulant (DOAC), is a thrombin inhibitor that has been approved for the prevention of ischemic stroke in patients with atrial fibrillation (AF). Dabigatran is associated with a substantially lower risk of intracranial hemorrhage than warfarin, with absolute rates of hemorrhage that approximate those seen with aspirin (ASA) treatment. 6 Dabigatran inhibits both clot-bound and free thrombin, which may make it particularly effective at reducing early recurrent events in patients with unstable thrombus and/or thrombogenic vascular lesions. In addition, dabigatran is likely to be more efficacious than ASA in preventing recurrent cardioembolic stroke in patients with covert AF. A recently completed single-arm, open-label trial demonstrated the feasibility and safety of treating patients with TIA/minor stroke with dabigatran within 24 h of onset. 7 DATAS II is aimed at determining the safety of early anticoagulation with dabigatran compared with aspirin in acute cerebrovascular syndrome patients without diagnosed AF. The design includes serial magnetic resonance imaging (MRI) to identify the frequencies and predictors of both symptomatic and asymptomatic HT associated with acute dabigatran and aspirin treatment.
Methods

Study design
This is a randomized, open label blinded endpoint trial registered with clinicaltrials.gov (NCT02295826). Patients with TIA/minor ischemic stroke (National Institutes of Health Stroke Scale (NIHSS) 9) within 72 h of symptom onset are randomized 1:1 to dabigatran 150 mg BID for 30 days or ASA 81 mg for 30 days (Figure 1 ).
Patient population
Three hundred patients from six Canadian stroke centers will be enrolled. Eligible patients are randomized within 72 h of symptom onset after baseline MRI with diffusion-weighted images (DWIs), carotid imaging, and electrocardiograph. Detailed inclusion and exclusion criteria are shown in Table 1 . Large DWI lesions (25 ml) are excluded due to an increased risk of HT. 8 Treatment ASA group. Participants randomized to aspirin are loaded with 325 mg of ASA, followed by 81 mg/day. Study ASA is provided to patients. Adherence is assessed at study visits by pill counts.
Dabigatran group. Participants randomized to dabigatran are treated with 150 mg twice daily for 30 days. The dose is reduced to 110 mg twice daily in participants 80 years of age and/or an estimated GFR of 30-50 ml/min (calculated using a weight-based equation). After 30 days, participants are treated with ASA 81 mg daily unless an indication for anticoagulation is established (e.g. AF).
Primary outcome
The primary outcome is the rate of symptomatic HT, defined as a parenchymal hematoma associated with-4-point increase in NIHSS score within five weeks of treatment initiation.
Secondary outcomes
Secondary outcomes include the rate of asymptomatic HT, recurrent ischemic stroke, and progression/recurrence of DWI lesions seen on the day 30 study MRI sequence on follow-up MRI (supplementary Table 1 ). All images will be read by central readers blinded to treatment allocation.
Data Monitoring Committee (DMC)
An independent DMC meets after every 50 patients randomized (supplementary Table 2 ). No interim analyses are planned. The DMC may recommend that the trial be halted or the protocol amended at any point.
Sample size estimates
The frequency of symptomatic HT in patients treated with antiplatelet agents has been found in previous studies to be <1%. 9 The maximum acceptable rate of symptomatic HT associated with an acute therapy should not International Journal of Stroke, 12 (8) exceed that of tPA (6.4%). 9 A sample size of 136 participants per group is required to demonstrate an absolute between-group difference in the rate of total HT of 5.6% with 80% power, assuming alpha ¼ 5%. A total trial size of 272 participants is therefore required. The sample size was inflated to 300 (150 patients per group) to account for participants lost to follow up or nonadherent to treatment allocation.
Statistical analyses
One-tailed t-test will be used to demonstrate if there is an absolute difference between intervention groups as it is unlikely that ASA will have a higher rate of HT than dabigatran. Univariate linear regression and logistic regression analyses will be used to test the relationship between imaging endpoints, hypothesized clinical factors, and risk of all forms of HT. in AF patients. The risk of recurrent stroke is front loaded but the lack of data with respect to the timing of initiation of dabigatran, or any other DOAC, within 14 days of a cerebrovascular event precludes any evidence-based recommendations. This trial enrolling acute ischemic strokes with NIHSS 9 is a necessary first step toward achieving that goal.
Study organization and funding
Summary and conclusions
This is the first randomized study of a novel anticoagulant in the acute TIA/stroke population. Demonstrating the safety of short-term dabigatran therapy will facilitate the design of subsequent potential trials to assess efficacy for prevention of early recurrent brain ischemia.
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